Dec 1, 2015 10:02 PM
http://www.fiercepharma.com/story/bristo...2015-12-01
EXCERPT: After winning FDA approval Monday, the latest multiple myeloma treatment--Empliciti, from Bristol-Myers Squibb ($BMY) and AbbVie ($ABBV)--is about to hit the scene. And like its rivals in the field, it'll be pricey. The ongoing monthly cost of the new med, to be used in combination with Celgene's ($CELG) Revlimid and dexamethasone, is about $10,000, Bristol-Myers Squibb spokeswoman Audrey Abernathy told FiercePharma in an emailed statement. Along with a two-month induction period, that figure puts the first-year annual cost of the drug at about $142,000 in the U.S....
EXCERPT: After winning FDA approval Monday, the latest multiple myeloma treatment--Empliciti, from Bristol-Myers Squibb ($BMY) and AbbVie ($ABBV)--is about to hit the scene. And like its rivals in the field, it'll be pricey. The ongoing monthly cost of the new med, to be used in combination with Celgene's ($CELG) Revlimid and dexamethasone, is about $10,000, Bristol-Myers Squibb spokeswoman Audrey Abernathy told FiercePharma in an emailed statement. Along with a two-month induction period, that figure puts the first-year annual cost of the drug at about $142,000 in the U.S....